{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:08:55Z","timestamp":1773677335610,"version":"3.50.1"},"reference-count":26,"publisher":"Pan African Medical Journal","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pan Afr Med J"],"abstract":"<jats:p>Introduction: cardiovascular disease is a growing concern in Africa, with coronary artery disease emerging as a leading cause of mortality. Despite strong evidence and international guidelines recommending secondary prevention therapy post-acute coronary syndrome (ACS)-including antiplatelet agents, statins, beta blockers, and angiotensin-converting enzyme (ACE) inhibitors-suboptimal use remains a concern, especially in low- and middle-income countries. This study aimed to quantify the use of guideline-recommended secondary prevention medications after ACS in Kenya using the data from the Kenya Heart Registry study.\n\n \n\nMethods: a cohort study was conducted using data from the Kenya Heart Registry across three hospitals in Kenya from 2019 to 2023. Adult patients (\u226518 years) diagnosed with ACS (ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), or unstable angina (UA)) were included. Clinical and sociodemographic data were extracted, including pharmacotherapy at presentation and discharge. Descriptive statistics and multivariate logistic regression (odds ratio (OR) and 95% confidence intervals) were used to assess patterns and predictors of medication use at discharge.\n\n \n\nResults: a total of 247 patients were included (168 STEMI, 79 NSTEMI\/UA). Majority, 77.7% were males and 39.3% were above age of 65 years. More than 70% of the patients were overweight or obese. Use of secondary prevention therapy was low at home but increased significantly during hospitalization and remained high at discharge. At discharge, 91.4% of STEMI and 89.9% of NSTEMI\/UA patients received aspirin; 88.3% and 84.8%, respectively, received statins. The odds of receiving a beta blocker at discharge were higher among patients with diabetes (OR=2.59) and dyslipidemia (OR=2.46), while patients with hypertension had higher odds of receiving ARB (OR=5.28).\n\n \n\nConclusion: despite better in-hospital and discharge prescribing patterns, suboptimal pre-hospital medication use and underutilization of certain agents like ticagrelor at discharge highlight gaps in care. Tailored interventions-such as provider training, patient education, and strengthened transition-of-care protocols-are needed to improve long-term adherence to guideline-directed medical therapy after ACS in Kenya, particularly among high-risk groups.<\/jats:p>","DOI":"10.11604\/pamj.2026.53.70.48714","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:33:50Z","timestamp":1773671630000},"source":"Crossref","is-referenced-by-count":0,"title":["Utilization of evidence-based secondary preventive therapies post acute coronary syndrome: a heart registry cohort study in Kenya"],"prefix":"10.11604","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0056-560X","authenticated-orcid":false,"given":"Anthony","family":"Ochola","sequence":"first","affiliation":[{"name":"Department of Medicine, Aga Khan University, Nairobi, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7957-5426","authenticated-orcid":false,"given":"Jasmit","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Aga Khan University, Nairobi, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Jeilan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Aga Khan University, Nairobi, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harun","family":"Otieno","sequence":"additional","affiliation":[{"name":"Department of Medicine, Aga Khan University, Nairobi, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Barasa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Aga Khan University, Nairobi, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine","family":"Akwanalo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Moi Teaching and Referral Hospital, Eldoret, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benard","family":"Gitura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kenyatta National Hospital, Nairobi, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-0387","authenticated-orcid":false,"given":"Mzee","family":"Ngunga","sequence":"additional","affiliation":[{"name":"Department of Medicine, Aga Khan University, Nairobi, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4870","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Yuyun MF, Sliwa K, Kengne AP, Mocumbi AO, Bukhman G. Cardiovascular diseases in sub-Saharan Africa compared to high-income countries: an epidemiological perspective. Glob Heart. 2020 Feb 12;15(1):15. PubMed | Google Scholar","DOI":"10.5334\/gh.403"},{"key":"ref1","unstructured":"World Health Organization. The top 10 causes of death. Accessed on July 21, 2025."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Almahmeed W, Arnaout MS, Chettaoui R, Ibrahim M, Kurdi MI, Taher MA et al. Coronary artery disease in Africa and the Middle East. Ther Clin Risk Manag. 2012:8:65-72. PubMed | Google Scholar","DOI":"10.2147\/TCRM.S26414"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Shehu MN, Adamu UG, Ojji DB, Ogah OS, Sani MU. The pandemic of coronary artery disease in the sub-Saharan Africa: what clinicians need to know. Curr Atheroscler Rep. 2023 Sep;25(9):571-578. PubMed | Google Scholar","DOI":"10.1007\/s11883-023-01136-9"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Pattanayak JM, Gelfand EV. Complications of acute coronary syndrome. Management of Acute Coronary Syndromes. 2009 Apr 17:141-72. Google Scholar","DOI":"10.1002\/9780470745465.ch6"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006 Nov 25;333(7578):1091. PubMed | Google Scholar","DOI":"10.1136\/bmj.38985.646481.55"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Kernis SJ, Harjai KJ, Stone GW, Grines LL, Boura JA, O'Neill WW et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol. 2004 May 19;43(10):1773-9. PubMed | Google Scholar","DOI":"10.1016\/j.jacc.2003.09.071"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003 Feb 25;107(7):966-72. PubMed | Google Scholar","DOI":"10.1161\/01.CIR.0000051362.96946.15"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Claessen BE, Guedeney P, Gibson CM, Angiolillo DJ, Cao D, Lepor N et al. Lipid management in patients presenting with acute coronary syndromes: a review. J Am Heart Assoc. 2020 Dec 15;9(24):e018897. PubMed | Google Scholar","DOI":"10.1161\/JAHA.120.018897"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Wessler JD, Stant J, Duru S, Rabbani L, Kirtane AJ. Updates to the ACCF\/AHA and ESC STEMI and NSTEMI guidelines: putting guidelines into clinical practice. Am J Cardiol. 2015 Mar 14;115(5 Suppl):23A-8A. PubMed | Google Scholar","DOI":"10.1016\/j.amjcard.2015.01.004"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Tubaro M. ESC 2017 STEMI Guidelines: a step forward for a better cure. Eur Heart J Cardiovasc Pharmacother. 2018 Jul 1;4(3):133-135. PubMed | Google Scholar","DOI":"10.1093\/ehjcvp\/pvy013"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Vermeer N, Bajorek B. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice. J Clin Pharm Ther. 2008 Dec;33(6):591-601. PubMed | Google Scholar","DOI":"10.1111\/j.1365-2710.2008.00950.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Ariss RW, Minhas AMK, Issa R, Ahuja KR, Patel MM, Eltahawy EA et al. Demographic and regional trends of mortality in patients with acute myocardial infarction in the United States, 1999 to 2019. Am J Cardiol. 2022 Feb 1:164:7-13. PubMed | Google Scholar","DOI":"10.1016\/j.amjcard.2021.10.023"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011 Oct 1;378(9798):1231-43. PubMed | Google Scholar","DOI":"10.1016\/S0140-6736(11)61215-4"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Mathews R, Wang TY, Honeycutt E, Henry TD, Zettler M, Chang M et al. Persistence with secondary prevention medications after acute myocardial infarction: insights from the TRANSLATE-ACS study. Am Heart J. 2015 Jul;170(1):62-9. PubMed | Google Scholar","DOI":"10.1016\/j.ahj.2015.03.019"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA . 2007 Jan 10;297(2):177-86. PubMed | Google Scholar","DOI":"10.1001\/jama.297.2.177"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Sani MU, Mayosi BM. The pacemaker and ICD reuse programme of the pan-African Society of Cardiology. Heart. 2017 Dec;103(23):1844-1845. PubMed | Google Scholar","DOI":"10.1136\/heartjnl-2017-311462"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Zubaid M, Rashed WA, Almahmeed W, Al-Lawati J, Sulaiman K, Al-Motarreb A et al. Management and outcomes of Middle Eastern patients admitted with acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE). Acta Cardiol. 2009 Aug;64(4):439-46. PubMed | Google Scholar","DOI":"10.2143\/AC.64.4.2041607"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Fox KA, Goodman S, Klein Wf, Brieger D, Steg P, Dabbous O et al. Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002 Aug;23(15):1177-89. PubMed | Google Scholar","DOI":"10.1053\/euhj.2001.3081"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Krishnan M, Zachariah G, Venugopal K, Mohanan P, Harikrishnan S, Sanjay G et al. Prevalence of coronary artery disease and its risk factors in Kerala, South India: a community-based cross-sectional study. BMC Cardiovasc Disord. 2016 Jan 14:16:12. PubMed | Google Scholar","DOI":"10.1186\/s12872-016-0189-3"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Yusuf S, Hawken S, \u00d4unpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep;364(9438):937-52. PubMed | Google Scholar","DOI":"10.1016\/S0140-6736(04)17018-9"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Lopez-Jimenez F, Jacobsen SJ, Reeder GS, Weston SA, Meverden RA, Roger VL. Prevalence and secular trends of excess body weight and impact on outcomes after myocardial infarction in the community. Chest. 2004 Apr;125(4):1205-12. PubMed | Google Scholar","DOI":"10.1378\/chest.125.4.1205"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Ogah O, Madukwe O, Onyeonoro U, Chukwuonye I, Ukegbu A, Akhimien M et al. Cardiovascular risk factors and non-communicable diseases in Abia state, Nigeria: report of a community-based survey. IJIMR. 2013;2(1):57-68. Google Scholar","DOI":"10.14194\/ijmbr.2110"},{"key":"ref23","unstructured":"Delport R. Towards developing guidelines and systems of care to facilitate early reperfusion for ST-elevation myocardial infarction in Africa. Cardiovascular Journal of Africa. 2014;25(6):256-8.. PubMed | Google Scholar"},{"key":"ref24","unstructured":"Eagle KA, Montoye CK, Riba AL, DeFranco AC, Parrish R, Skorcz S et al. Guideline-based standardized care is associated with substantially lower mortality in medicare patients with acute myocardial infarction: the American College of Cardiology\u00b4s Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol. 2005 Oct 4;46(7):1242-8. PubMed | Google Scholar"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention.J Am Coll Cardiol. 2010 Jul 20;56(4):254-63. PubMed | Google Scholar","DOI":"10.1016\/j.jacc.2010.05.008"}],"container-title":["Pan African Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:34:00Z","timestamp":1773671640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.panafrican-med-journal.com\/content\/article\/53\/70\/full\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":26,"URL":"https:\/\/doi.org\/10.11604\/pamj.2026.53.70.48714","relation":{},"ISSN":["1937-8688"],"issn-type":[{"value":"1937-8688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"article-number":"48714"}}